TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Systemic Solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Hemodynamic Preeclamptic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CHIKV serum antibody Geometric Mean Titer using PRNT50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean fold change in PRNT50 anti-CHIKV antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The proportion of subjects with at least a 4-fold increase in CHIKV serum antibody titer, using PRNT50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Jaw Use Limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of anxiety and/or depression disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood transfusion within 14 days of transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence and severity of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum level of Indolepropionic acid [IPA]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum level of indoleacetic acid [IAA]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum level of kynurenic acid [KYNA]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change on Hamilton Depression Rating Scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area of Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Elevated Responses of Skin to Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Immunogenicity Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference of BOLD signal in hypothalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genetic loci identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic assessment of Immune cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of fibrosis in biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicardial adipose tissue measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure percentage of the diagnostic strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Microbiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neural reward sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IFIS cases observed during operation
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in peri-implant probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Improvement in Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lesion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Participant satisfaction with either treatment arm
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endothelial function marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in clinical outcomes related to acute dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tinnitus Handicap Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional synthesis rate of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival after right heart catheterization
Endpoint domain: Mortality/survival
Primary endpoint: Change in Sino-Nasal Outcome Test scores (SNOT-22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence of atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in peri-orbital and/or peri-oral wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incremental area under the postprandial glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incremental peak postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fungal culture result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Visits to the Emergency Department by the Person With Dementia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Visits to the Emergency Department by the Caregiver of the Person With Dementia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Area under the concentration-time curve (AUC0-∞) of tiotropium in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of tiotropium in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of tiotropium that was eliminated in urine (Ae0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Corneal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean percent change in intact parathyroid hormone (PTH) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Volume of Distribution (VT) of [18F]-FBA-A20FMDV2 in the Whole Lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Depth of primary insertion of tracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tumor Tissue Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in Wheelchair Skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from baseline in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discontinuation of Rebif treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Sum of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response (partial response and complete response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of the first postoperative analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome using the Olerud-Molander score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Antiinflammatory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in housing stability status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Circulating steroidal hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite End Point of Acute Rejection, Graft Loss or Patient Death
Endpoint domain: Mortality/survival
Primary endpoint: Wrist range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Sleep Disorders
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sensitivity of 18F-FDG PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perioperative complication positivity before discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical scale of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) of IPI-504
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depression severity measured by HDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in agitation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for Tivozanib Hydrochloride or Sunitinib
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Asymptomatic Significant LVEF Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean annual change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean annual change in FEV1/FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Delaying labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neck Disability Index Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Difference in the Total Number of Errors From Paired Associates Learning (PAL) Module
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Difference in First Attempt Memory Score From Paired Associates Learning (PAL) Module
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Difference in Stop Signal Reaction Time From Stop Signal Task (SST) Module
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average Retinal Nerve Fiber Layer Thickness (RNFLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Number of Pressure Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Kidney quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum Levels of carboxymethyl-lysine (CML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in vascular calcium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: adherence to guideline-recommended surveillance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of newly-identified late effects of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in Standardized patient Evaluation of Eye Dryness (SPEED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Meibomian Gland Score (MGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tear Break-Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Leucocyte LC3 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of preventable adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: portal hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days from decision to test to receiving genetic test results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of occurrence of overall toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Treatment Attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SERT Binding Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Evaporative Air Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in sustainable healthy eating behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PTSD Symptoms as Measured by the PTSD Checklist (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Impairment as Measured by the Mental Health Subscale of The Short Form 36 Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Limit of Agreement (LOA) for full retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limit of Agreement (LOA) for retinal nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limit of Agreement (LOA) for ganglion cell complex thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limit of Agreement (LOA) for optic disc measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision for full retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision for retinal nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Audiometry - Pure Tone Average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Perforation in the Treated Ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fibroid-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in children's sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-corrected area-under-the serum insulin concentration vs. time curve (AUC0-540 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the glucose infusion rate (GIR AUC0-540 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of hospital days per child-year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment outcomes for deep venous thromboses or pulmonary emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in vascular calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in phosphorus calcium product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in PTHi serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Patients With Stable Disease at 4 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experienced Severe Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Forehead Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of blood hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet Reactivity Unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fertility hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in bone pain according to Visual Analog Scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of amino acids in ileal digesta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with spirometry confirmed COPD diagnosis according to Fixed Ratio Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of subjects with spirometry confirmed COPD diagnosis according to Lower Limit of Normal (LLN) Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of subjects who self-reported physician diagnosis of COPD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: characterization of physical and developmental phenotype of HPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spectrum of clinical characteristics of HPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychosocial impact of HPE on the family system
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Structural and process quality of psychosocial services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Bone mineral density (BMD) testing rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Venous Thromboembolism Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identification of chronic hepatitis C virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of testing for HCV screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in ADAS-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median time to loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMR T2 mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects Against Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression-free Survival (PFS) based on PSA velocity
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival (PFS) based on absolute PSA value
Endpoint domain: Mortality/survival
Primary endpoint: Change in percentage of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in concentration of blood glucose (AC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV risk behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Success of the restorative procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Overall Malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of Non-melanoma Skin Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose of SBP-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescribing for respiratory encounters
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: live born delivery rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients in ENT remission without relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (confirmed and unconfirmed response, complete response, partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ascending Aorta Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol-related consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Realization of human papillomavirus vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Survival of shI-TAR-CCR5RZ-marked cells in the peripheral blood
Endpoint domain: Mortality/survival
Primary endpoint: Change in Time in Range (TIR) in percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pharayngocutaneous Fistula Development
Endpoint domain: Adverse events/effects